New ASCO guideline for HR+ breast cancer

Women with hormone receptor positive breast cancer should consider ten years of endocrine therapy instead of the previously recommended five, an updated guideline from the American Society of Clinical Oncology says.

Presented at ASCO’s annual meeting in Chicago and simultaneously published in the JCO, the guideline recommends ten years of tamoxifen for premenopausal women with non-metastatic HR+ breast cancer.

For postmenopausal women it recommends a minimum of five years of adjuvant therapy